Systemic treatment of advanced esophageal squamous cell carcinoma (ESCC) mainly
consists of cytotoxic agents, aiming to palliate symptoms and prolong survival. Cisplatin and …

Background Patients with advanced or metastatic oesophageal squamous cell carcinoma
have poor prognosis and few treatment options after first-line therapy. We aimed to assess …

Esophageal cancer (EC) is an aggressive malignancy with an increasing incidence and a
poor prognosis. EC is histologically divided into two major categories: adenocarcinoma …

Oesophageal cancer is the seventh most common cancer worldwide, with 604 000 new
cases diagnosed in 2020. It is the sixth most common cause of cancer-related mortality, with …

Esophageal cancer is the sixth most common cause of cancer deaths worldwide.
Adenocarcinoma is more common in North America and Western European countries …

Upper gastrointestinal tract cancers originating in the esophagus, esophagogastric junction
(EGJ), and stomach constitute a major health problem around the world. An estimated …

The objective of this article was to review clinical trials that used antineoplastic second-line
chemotherapy and/or targeted therapies in patients with esophageal cancer after first-line …

Abstract Lessons Learned Apatinib has potential as an effective and safe second-line or
higher treatment for patients with chemotherapy-refractory esophageal squamous cell …

Purpose The aim of this study was to assess the cost-effectiveness of camrelizumab
immunotherapy versus docetaxel or irinotecan chemotherapy as second-line therapy for …

The prognosis of advanced esophageal cancer (EC) remains poor, and few effective agents
are available. For advanced EC patients, a combination of platinum and fluoropyrimidine is …